These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Nitrendipine: evaluation of the duration of the antihypertensive effect at different doses using the conventional method and ambulatory monitoring of arterial pressure].
    Author: Giarrizzo C, Germanò G, Leonetti-Luparini R, Ferri C, Caparra A, Coia F, Santucci A.
    Journal: Cardiologia; 1990 Sep; 35(9):751-7. PubMed ID: 2091826.
    Abstract:
    To evaluate the effect-duration of nitrendipine in 20 moderate essential hypertensives (aged from 42 to 66, mean +/- SD: 55 +/- 7) when treated with 20 mg once or twice a day, we utilized the blood pressure standard method of measurement and the ambulatory monitoring. Blood pressure determinations were made during the follow-up at 2- week intervals for 3 months, each measurement being made with a mercury sphygmomanometer, 24 +/- 3 hours after the last dose; laboratory parameters, 2 24-hour blood pressure monitoring (ICR 5200, Spacelabs) and standard ECG were performed at baseline and after 3 months. Following a 2-week run-in period with placebo bid (at 10.00 am and 10.00 pm) a 20 mg morning dose of nitrendipine was started continuing the administration of the placebo tablet at 10.00 pm. The dosage was changed to a twice active daily regimen, with an increase in the daily dose (20 mg twice a day) in those patients whose diastolic blood pressure remained greater than 90 mmHg after a 4-week control. After the twelfth week, another 2-week placebo run-in followed the active treatment. Supine blood pressure recorded after 3-month therapy, showed a significant (p less than 0.0001) reduction in both systolic and diastolic mean values (22/15 mmHg) at the end of active treatment in the 16 patients who ended the trial. In particular, the responders to 20 mg (5 patients) showed a blood pressure reduction of 18 mmHg in comparison with the run-in period; in the other group of responders to increasing dosage of 40 mg (11 patients), we observed a 8 mmHg diastolic blood pressure reduction at 28 days and a successive 7 mmHg at the end of the treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]